Medical Training AIPsoriasis Systemic and Biologic Therapy
Work through this track to select, sequence, and monitor systemic and biologic therapy for moderate-to-severe psoriasis, including comorbid psoriatic arthritis.
What this track covers
This track covers psoriasis pathophysiology and phenotypes, topical and traditional systemic options, and the major biologic classes (TNF, IL-17, IL-23, IL-12/23 inhibitors) used when disease is moderate to severe. It also addresses pre-treatment screening, comorbidity management including psoriatic arthritis and cardiovascular risk, and considerations for pregnancy, pediatric, and elderly patients.
What you will practice
- Distinguishing plaque, guttate, pustular, and erythrodermic phenotypes
- Matching disease severity and comorbidities to a therapy class
- Sequencing workup before starting a systemic or biologic agent
- Recognizing screening and monitoring needs specific to each drug class
- Identifying red flags for psoriatic arthritis and coordinating referral
Simulator scenario
A patient with longstanding plaque psoriasis presents with new joint pain and morning stiffness, requiring the clinician to assess for psoriatic arthritis and reconsider the treatment plan.
Board question topics
- Mechanism of action across biologic classes
- Pre-treatment screening requirements
- Psoriatic arthritis recognition and workup
- Special population treatment considerations
Ask the tutor
The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.
Free during the beta. Sign in with your email, no password.
Start free